- Home
- PULM vs NRXS Comparison
PULM vs NRXS Comparison
Compare PULM & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- NRXS
- Stock Information
- Founded
- PULM 2003
- NRXS 2011
- Country
- PULM United States
- NRXS United States
- Employees
- PULM N/A
- NRXS N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- NRXS
- Sector
- PULM Health Care
- NRXS
- Exchange
- PULM Nasdaq
- NRXS Nasdaq
- Market Cap
- PULM 21.0M
- NRXS 17.3M
- IPO Year
- PULM N/A
- NRXS 2023
- Fundamental
- Price
- PULM $6.11
- NRXS $2.85
- Analyst Decision
- PULM
- NRXS
- Analyst Count
- PULM 0
- NRXS 0
- Target Price
- PULM N/A
- NRXS N/A
- AVG Volume (30 Days)
- PULM 40.5K
- NRXS 31.4K
- Earning Date
- PULM 11-08-2024
- NRXS 11-12-2024
- Dividend Yield
- PULM N/A
- NRXS N/A
- EPS Growth
- PULM N/A
- NRXS N/A
- EPS
- PULM N/A
- NRXS N/A
- Revenue
- PULM $10,005,000.00
- NRXS $2,456,219.00
- Revenue This Year
- PULM N/A
- NRXS $383.16
- Revenue Next Year
- PULM $1.00
- NRXS N/A
- P/E Ratio
- PULM N/A
- NRXS N/A
- Revenue Growth
- PULM 47.05
- NRXS N/A
- 52 Week Low
- PULM $1.55
- NRXS $2.00
- 52 Week High
- PULM $8.44
- NRXS $3.89
- Technical
- Relative Strength Index (RSI)
- PULM 51.10
- NRXS 61.57
- Support Level
- PULM $5.95
- NRXS $2.48
- Resistance Level
- PULM $6.30
- NRXS $2.83
- Average True Range (ATR)
- PULM 0.43
- NRXS 0.27
- MACD
- PULM -0.10
- NRXS 0.06
- Stochastic Oscillator
- PULM 11.86
- NRXS 56.82
About PULM Pulmatrix Inc.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).